GlassScriptPhysician profile
Kaditam V Reddy
NPI 1770584245
$19,332.46
in general payments reported to CMS, 2019-2025
70 companies · $3,047 in 2025
The $3,047 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $1,888 · 2021: $2,952 · 2022: $3,184 · 2023: $2,984 · 2024: $3,469 · 2025: $3,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,379 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,379.27 |
| Education | $120.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,575.45 | 2020-2025 | |
| Biogen, INC. | $1,152.11 | 2019-2025 | Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $1,021.50 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Emd Serono, INC. | $977.89 | 2019-2025 | Mavenclad |
| Pfizer INC. | $945.06 | 2019-2025 | |
| Csl Behring | $908.46 | 2019-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $856.78 | 2019-2025 | |
| Amgen INC. | $639.90 | 2019-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $610.79 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $582.39 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $564.33 | 2019-2025 | |
| Lundbeck LLC | $532.93 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $457.07 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Allergan, INC. | $456.43 | 2019-2022 | |
| Genentech USA, INC. | $416.61 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $402.63 | 2019-2024 | Gocovri, Apokyn |
| Alexion Pharmaceuticals, INC. | $402.58 | 2019-2025 | Ultomiris |
| Ucb, INC. | $354.31 | 2019-2025 | Briviact, Rystiggo |
| Argenx US, INC. | $334.40 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $317.72 | 2021-2025 | Hyqvia, Gammagard |
| Genzyme Corporation | $302.31 | 2019-2023 | |
| Merz Pharmaceuticals, LLC | $291.99 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Acorda Therapeutics, INC | $277.34 | 2021-2024 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $274.41 | 2020-2023 | Rytary |
| Kyowa Kirin, INC. | $262.31 | 2021-2024 | Nourianz |
| Supernus Pharmaceuticals, INC. | $261.45 | 2019-2022 | |
| Grifols USA, LLC | $239.31 | 2019-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $210.91 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $209.39 | 2019-2025 | Nuplazid |
| Neurelis, INC. | $207.24 | 2023-2025 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $196.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $186.33 | 2021 | |
| Celgene Corporation | $185.86 | 2024-2025 | Zeposia |
| Sumitomo Pharma America, INC. | $176.30 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $172.86 | 2023-2025 | Symbravo, Sunosi |
| Tg Therapeutics, INC. | $163.20 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $161.19 | 2021-2023 | Ponvory |
| Azurity Pharmaceuticals, INC. | $148.75 | 2023-2025 | Horizant, Horizant |
| Avanir Pharmaceuticals, INC. | $107.99 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $99.08 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $97.34 | 2021-2024 | Wainua |
| Almatica Pharma LLC | $95.48 | 2021-2023 | Gralise |
| Livanova USA, INC. | $94.54 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $90.18 | 2022 | |
| Adamas Pharmaceuticals, INC. | $89.83 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $82.94 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $73.79 | 2023-2025 | Ztlido |
| Zyla Life Sciences, INC. | $73.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $70.90 | 2022-2023 | Uplizna |
| Upsher-Smith Laboratories LLC | $67.83 | 2021-2023 | |
| C2n Diagnostics, LLC | $66.47 | 2025 | Precivityad2 |
| Genentech, INC. | $63.73 | 2024 | Ocrevus |
| Ani Pharmaceuticals, INC. | $63.35 | 2024 | Purified Cortrophin Gel |
| Abbott Laboratories | $59.62 | 2021-2023 | Infinity |
| Alnylam Pharmaceuticals INC. | $57.10 | 2022-2024 | Onpattro |
| Merz North America, INC. | $54.73 | 2019-2020 | |
| Vertiflex, INC. | $54.30 | 2019 | |
| Impel Pharmaceuticals INC. | $45.94 | 2023 | Trudhesa |
| Octapharma USA, INC. | $45.03 | 2023-2024 | Panzyga |
| Assertio Therapeutics, INC. | $42.79 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $41.70 | 2021-2023 | Firdapse |
| Boston Scientific Corporation | $39.66 | 2021-2024 | |
| Ibsa Pharma INC. | $39.61 | 2020 | |
| Vertical Pharmaceuticals, LLC | $34.93 | 2019 | |
| Banner Life Sciences, LLC | $34.69 | 2022 | |
| Tanabe Pharma America, INC. | $33.76 | 2019-2025 | Radicava |
| Bio Products Laboratory USA, INC. | $24.97 | 2023 | Gammaplex, Coagadex |
| Medtronic Vascular, INC. | $21.44 | 2019 | |
| Promius Pharma LLC | $15.00 | 2019 | |
| Avion Pharmaceuticals | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaditam Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.